Weak economic growth, limited government spending, and high inflation—particularly in food prices—have worsened living standards, pushing more people into poverty, and increasing the risk of food ...

Discover Amneal Pharmaceuticals' Q1 2025 insights, featuring revenue growth, CREXONT’s expansion, biosimilar contributions, and innovative drug ...

The greater degree of control over integrating its equipment and processes also improved its pricing power, margins, and customer switching costs. We expect Chart will produce $4.74 billion in 2025 ...

Twist Bioscience's silicon-based DNA writing platform offers competitive advantages in synthetic DNA, NGS consumables, and ...

Mammary gland fibroblasts are highly plastic and transition through distinct states during development and disease. A new ...

BridgeBio's valuation relies on the commercialization of Attruby, but the drug's full potential may be undermined by tafamidis’ patent extension, introduction of generic alternatives, and other ...

GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.